Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Current Leases (2018 - 2026)

AdaptHealth has reported Current Leases over the past 8 years, most recently at $17.7 million for Q4 2025.

  • For Q4 2025, Current Leases rose 23.66% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, up 23.66%, while the annual FY2025 figure was $17.7 million, 23.66% up from the prior year.
  • Current Leases for Q4 2025 was $17.7 million at AdaptHealth, up from $15.3 million in the prior quarter.
  • Over five years, Current Leases peaked at $30.3 million in Q3 2024 and troughed at $2.2 million in Q4 2022.
  • A 5-year average of $16.3 million and a median of $15.4 million in 2021 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: crashed 85.69% in 2022 and later skyrocketed 312.57% in 2023.
  • Year by year, Current Leases stood at $15.4 million in 2021, then crashed by 85.69% to $2.2 million in 2022, then surged by 312.57% to $9.1 million in 2023, then skyrocketed by 56.93% to $14.3 million in 2024, then rose by 23.66% to $17.7 million in 2025.
  • Business Quant data shows Current Leases for AHCO at $17.7 million in Q4 2025, $15.3 million in Q3 2025, and $15.2 million in Q2 2025.